Pharmacological effects of Upadacitinib extended-release tablets as a JAK1 inhibitor

Upadatinib is an oral sustained-release tablet that belongs to the Janus kinase (JAK) inhibitor family and is a selective JAK1 inhibitor. JanusKinases are a class of intracellular enzymes that participate in the signaling of a variety of cytokines, especially playing a key role in immune and inflammatory responses. Upadatinib reduces the inflammatory response by specifically binding to and inhibiting the enzymatic activity of JAK1 and blocking the cytokine-mediated signal transduction pathway.

JAK1 is involved in the signaling of a variety of pro-inflammatory cytokines (such as IL-6, IFN-γ, etc.). By inhibiting JAK1, upadatinib interferes with the downstream signals of these cytokines and regulates the activation and function of immune cells. This mechanism can effectively reduce chronic inflammation caused by abnormal activation of the immune system, and is suitable for the treatment of autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.

Upadatinib adopts a sustained-release tablet form, which enables the drug to be slowly released in the body, maintains a relatively stable blood concentration, and avoids excessive peak and valley fluctuations. This method of administration not only improves the sustainability of the efficacy, but also helps reduce the risk of side effects caused by sudden changes in drug concentration, and improves patients' tolerance and compliance with medication.

By highly selectively inhibiting JAK1, upadatinib effectively blocks the inflammatory pathway, helps patients reduce joint swelling, pain and other symptoms, and inhibits disease progression. Clinical trials have shown that upadatinib can significantly improve the clinical remission rate and quality of life of patients in multiple autoimmune diseases. It is one of the drugs with high clinical value in the current field of targeted therapy.

Reference materials:https://www.drugs.com/